Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. 

Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. 

Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors.

In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. 

The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). 

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

Innosuisse

Pureos Bioventures

Schroder Adveq

BioMedPartners

Bpifrance

High-Tech Grunderfonds

Jeito Capital

Kinled Holding

Morningside Venture Investments

Novo Holdings

RA Capital Management

Schroders Capital

Alentis Therapeutics

Anoat Therapeutics is a biotech company focused on developing treatments for cancer and fibrosis.

Anoat Therapeutics

Triveni Bio is a biotech company specializing in cancer treatment and fibrosis reversal.

Triveni Bio

Attovia is a biotech company dedicated to developing innovative therapies for cancer and fibrosis.

Attovia

NorthSea Therapeutics is a biopharmaceutical company focused on developing treatments for liver diseases and fibrosis.

NorthSea Therapeutics

FoRx Therapeutics is a biotech company specializing in cancer treatment and fibrosis reversal.

FoRx Therapeutics

Galectin Therapeutics is a biopharmaceutical company focused on the development of therapies for fibrotic diseases, including cancer-related fibrosis.

Galectin Therapeutics

Travere Therapeutics is a biopharmaceutical company dedicated to developing treatments for rare and serious kidney diseases, including those related to cancer treatment.

Travere Therapeutics

Jnana Therapeutics is a biotech company focused on developing small molecule therapies for neurodegenerative diseases, including those associated with cancer treatment.

Jnana Therapeutics

SciClone Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapies for cancer and infectious diseases.

SciClone Pharmaceuticals

STADA is a pharmaceutical company specializing in the development and marketing of pharmaceutical products, including those for cancer treatment.

STADA

Faes Farma is a pharmaceutical company dedicated to the development and commercialization of pharmaceutical products, including those for cancer treatment.

Faes Farma

Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including those related to cancer treatment.

Aquestive Therapeutics

Alentis Therapeutics is a biotech company focused on developing treatments for cancer and reversing fibrosis by targeting Claudin-1, a protein involved in disease signaling and tumor cell growth.

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	May 6, 2024 7:58 AM	0538731d
public peers	general	May 6, 2024 7:58 AM	d0479cb0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:58 AM	9d470c14
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general
news basic	general	May 6, 2024 7:58 AM	e7167c18
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

CH:ALENTIS

Alentis Therapeutics